Quote:
Originally Posted by jonbxx
The report does acknowledge the limitations of passive monitoring of side effects, namely the Yellow Card system. The strands 2 to 4 are in place to supplement the passive system. They will also enhance knowledge of the sensitivity of Yellow Card reporting to utilise what data is collected in the most meaningful way.
We now have probably the biggest cohort for any post marketing surveillance in history. We are also developing better and better tools to analyse the data gathered, cross linking vaccination records with other medical records. If the post market surveillance for the COVID vaccine scheme is not sufficient to give confidence in the products, then I would be very wary of almost any other drug on the market as in almost all cases, the monitored population will be less than seen here
|
I was quite detailed about the failings of this system. The CDC followed about 10 million jabbed people so, no, we don't have the biggest cohort. (and they found significant side effects, as did the MHRA) Did you actually read what I wrote?